I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more Antibody Programs

 I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more Antibody Programs

I-Mab Biopharma Expands Collaboration with Wuxi Biologics for three more Antibody Programs

Shots:

  • I-Mab plans to license WuxiBody a proprietary platform from Wuxi for the development of three bispecific antibodies with focus on immuno-oncology and auto-immune
  • This colloboration is the expansion of 2017 agreement between the companies which was intended for development and manufacturing of I-Mab pipeline products
  • WuXiBody bispecifics have achieved 16g/L in cell culture titer, 95+% purity after one-step Protein A purification and 95+% yield for Protein A step

Click here to read full press release/ article | Ref: I-Mab Biopharma | Image: The Pharma Letter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post